Comparative Pharmacology
Head-to-head clinical analysis: SULFABID versus SULFACEL 15.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFABID versus SULFACEL 15.
SULFABID vs SULFACEL-15
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfonamide antibiotic that competitively inhibits dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydrofolate and thereby inhibiting bacterial folate synthesis.
Sulfacetamide inhibits bacterial dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydrofolate, thereby inhibiting folate synthesis and bacterial growth.
500 mg orally every 12 hours for 10-14 days.
Adults: 15 mg/kg orally every 6 hours for 10 days; maximum single dose 1 g.
None Documented
None Documented
Terminal elimination half-life: 8-12 hours in adults with normal renal function; prolonged to 20-50 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Expected ~6-9 hours based on related sulfacetamide; however, no specific data for SULFACEL-15. Clinical context: prolonged in renal impairment.
Renal: 80-90% unchanged via glomerular filtration and tubular secretion. Biliary: 5-10% as metabolites. Fecal: <5%.
Renal: ~85-90% unchanged; Biliary/Fecal: ~5-10% (metabolites and unchanged drug); ~5% eliminated via feces following biliary secretion.
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)